HMGB1 and neoplasm: Tumor cells undergoing immunogenic cell death (ICD) after various therapies, including hyperthermia, express calreticulin (CRT) on the cell surface and release tumor-specific antigens and “danger-associated molecular patterns” (DAMP), such as ATP, high mobility group box 1 protein I (HMGB1), type 1 interferons (IFNs), and heat-shock proteins (HSPs), thereby triggering a cascade of immune responses.